CONNECT BIOPHARMA HOLDINGS L

CNTBNASDAQ

🏆 #4307 by market capUS Equity

$242.44▲ $19.37 (+7.99%)

Simulated price

🔔

Track CNTB

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 8.0%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$68M

Small Cap

📈Revenue Growth (YoY)

-99.8%

Declining

📊Gross Margin

100.0%

High

💵FCF Margin

-1087.1%

Thin

⚖️P/S Ratio

23.2x

Expensive

Otter Score

Fair

No chart data available for CNTB.

Trading Snapshot

Day Range: $238.88 – $245.39
52-Week Range: $1.05 – $3.82
Volume: $2.12B
Avg Volume: $2.70B
Shares Outstanding: 63.0M
Next Earnings: Nov 11, 2026

Fundamentals Snapshot

Annual Revenue: $64,000
Last Q Revenue: $3M
P/E Ratio: -1.2
P/S Ratio: 23.2x
EPS (TTM): $-0.82
Dividend Yield: 0.00%
Dilution (1yr): +0.9%

Why Investors Own CNTB

✓High-growth profile — revenue up +13.2% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CONNECT BIOPHARMA HOLDINGS L

CNTB

Financial Trends

Revenue

$64K▼ −99.8% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$58M▲ +158.7% YoY

Free Cash Flow

−$52M▲ +112.0% YoY

Shares Outstanding

55.7M▲ +0.9% YoY

Net Cash

$38M▼ −$40M YoY

StockOtter · stockotter.space

About CONNECT BIOPHARMA HOLDINGS L

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

🦦